Icure Pharmaceutical Incorporation (KOSDAQ: 175250)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,953.00
-57.00 (-2.84%)
Dec 20, 2024, 9:00 AM KST
-8.74%
Market Cap 72.98B
Revenue (ttm) 60.61B
Net Income (ttm) 521.32M
Shares Out 37.37M
EPS (ttm) 13.88
PE Ratio 140.70
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 155,528
Open 1,980.00
Previous Close 2,010.00
Day's Range 1,940.00 - 2,010.00
52-Week Range 1,660.00 - 3,490.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Mar 21, 2025

About Icure Pharmaceutical Incorporation

Icure Pharmaceutical Incorporation, a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea. The company offers functional, nature-derived, derma, and customized cosmetics products. It also offers eye gel, hydro nude gel, lip gel mask, and functional patch products; and sheet, mud, foil, and melting masks. In addition, the company provides body and haircare products, including naturally derived hair and baby line, cleansing tissue, and wet wipes. Further, it offers perfumes, textile perfu... [Read more]

Industry Perfumes, Cosmetics, and Other Toilet Preparations
Founded 2000
Employees 218
Stock Exchange KOSDAQ
Ticker Symbol 175250
Full Company Profile

Financial Performance

In 2023, Icure Pharmaceutical Incorporation's revenue was 56.81 billion, a decrease of -4.31% compared to the previous year's 59.37 billion. Losses were -31.42 billion, -24.77% less than in 2022.

Financial Statements

News

There is no news available yet.